Concomitant 5-Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis.

We evaluated whether concomitant 5-aminosalicylic acid (5-ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib (n = 181), upadacitinib (n = 313), or filgotinib (n = 139) were included. Time to clinical remission was analyzed using interval-censored Cox models. Among the 633 patients treated with JAKi, 476 patients received 5-ASA, and 151 did not. Cumulative probability of remission at week 48 was similar with and without 5-ASA, at 81.3% and 77.0%, respectively. The adjusted hazard ratio for 5-ASA vs. no 5-ASA was 1.12 (95% CI 0.91-1.37, P = 0.519). We therefore found that concomitant 5-ASA did not significantly affect the time to clinical remission in UC patients treated with JAKi.